respiratory syncytial virus Archives -

Look out, Pfizer and GSK. Moderna is looking to make a swift dash to the finish line with

With filing due soon, Moderna stakes a claim to the RSV vaccine market

https://pharmaphorum.com/news/with-filing-due-soon-moderna-stakes-a-claim-to-the-rsv-vaccine-market/

Market Access/ News/ News

FDA starts review of Sanofi, AZ antibody for RSV prevention

Phil Taylor AstraZeneca, infectious disease, nirsevimab, respiratory syncytial virus, Sanofi 0 Comment

The clock has started ticking on the FDA’s review of Sanofi and AstraZeneca’s one-shot antibody to protect newborns

FDA starts review of Sanofi, AZ antibody for RSV prevention

https://pharmaphorum.com/news/fda-starts-review-of-sanofi-az-antibody-for-rsv-prevention/

Market Access/ News/ News

RSV vaccine race in balance as FDA sets May date for Pfizer decision

Phil Taylor fda, GSK, Pfizer, regulatory, respiratory syncytial virus, vaccine 0 Comment

The FDA has started its review of Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, fast-tracking the

RSV vaccine race in balance as FDA sets May date for Pfizer decision

https://pharmaphorum.com/news/rsv-vaccine-race-in-balance-as-fda-sets-may-date-for-pfizer-decision/

Market Access/ News/ News

AZ, Sanofi get first green light for RSV prophylactic antibody

Phil Taylor antibody, AstraZeneca, Beyfortus, nirsevimab, paediatrics, prevention, respiratory syncytial virus, Sanofi 0 Comment

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns

AZ, Sanofi get first green light for RSV prophylactic antibody

https://pharmaphorum.com/news/az-sanofi-get-first-green-light-for-rsv-prophylactic-antibody/

News/ News/ Sales and Marketing

After Haleon spinoff, GSK raises forecasts on ‘strong’ Q3

Phil Taylor Financial, GlaxoSmithKline, respiratory syncytial virus, Sales and Marketing, Shingrix, vaccines 0 Comment

In its first set of quarterly results since it separated from its consumer health business, GSK has exceeded

After Haleon spinoff, GSK raises forecasts on ‘strong’ Q3

https://pharmaphorum.com/news/after-haleon-spinoff-gsk-raises-forecasts-on-strong-q3/

News/ News/ R&D

Pfizer says maternal RSV shot gives strong protection to newborns

Phil Taylor GlaxoSmithKline, maternal, paediatric, Pfizer, respiratory syncytial virus, vaccine 0 Comment

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the

Pfizer says maternal RSV shot gives strong protection to newborns

https://pharmaphorum.com/news/pfizer-says-maternal-rsv-shot-gives-strong-protection-to-newborns/

Market Access/ News/ News

EU regulator lifts GSK amid torrid week for company’s pipeline

Phil Taylor cabotegravir, ema, GlaxoSmithKline, respiratory syncytial virus, vaccine 0 Comment

The EMA has delivered some good news to GSK on a new long-acting HIV drug and vaccine for

EU regulator lifts GSK amid torrid week for company’s pipeline

https://pharmaphorum.com/news/eu-regulator-lifts-gsk-amid-torrid-week-for-companys-pipeline/

Digital innovation drives vaccine development

News/ News/ R&D

GSK says RSV vaccine shows 94% efficacy in severe disease

Phil Taylor Bavarian Nordic, GlaxoSmithKline, infectious disease, Johnson & Johnson, Moderna, Pfizer, respiratory syncytial virus, vaccine 0 Comment

GSK’s vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also

GSK says RSV vaccine shows 94% efficacy in severe disease

https://pharmaphorum.com/news/gsk-says-rsv-vaccine-shows-94-efficacy-in-severe-disease/

Market Access/ News/ News

CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevention

Phil Taylor antibody, AstraZeneca, Beyfortus, CHMP, GlaxoSmithKline, nirsevimab, Pfizer, respiratory syncytial virus, Sanofi 0 Comment

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of

CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevention

https://pharmaphorum.com/news/chmp-says-yes-to-sanofi-astrazeneca-antibody-for-rsv-prevention/

Trending

respiratory syncytial virus

Login